Blinklab Limited (AU:BB1) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BlinkLab Limited has announced a key partnership with Dutch mental health service provider INTER-PSY to conduct a clinical trial for their AI-powered app designed to diagnose autism in children. This collaboration aims to refine the app’s algorithms and expedite regulatory approvals in the US and EU, addressing the urgent need for faster autism diagnostics, especially in females. The trial is a stepping stone towards an FDA 510(k) registration, signaling a potential breakthrough in reducing long wait times for autism diagnosis and treatment initiation.
For further insights into AU:BB1 stock, check out TipRanks’ Stock Analysis page.